文献速递乳腺癌头颈与中枢神经肿瘤

HER3-DXd治疗乳腺癌活动性脑转移的II期TUXEDO-3试验

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2025-01-01

TUXEDO-3是一项多中心、单臂II期试验,评估Patritumab deruxtecan(HER3-DXd)在乳腺癌活动性脑转移患者中的疗效与安全性。21例可评估患者中5例(24%)达到颅内缓解,主要终点达成;常见≥3级不良事件为中性粒细胞减少(14%)和腹泻(10%),无治疗相关死亡。

要点

  • HER3-DXd在乳腺癌活动性脑转移中颅内缓解率达24%,超过15%的主要终点阈值。
  • 常见≥3级不良事件为中性粒细胞减少(14%)和腹泻(10%),无治疗相关死亡。
  • 该结果提示HER3-DXd可能成为活动性脑转移患者的新治疗选择。

核心结论

  • HER3-DXd在乳腺癌活动性脑转移患者中显示出有前景的临床活性,可能提供新的治疗选择。

研究设计与样本

  • TUXEDO-3为多队列、多中心、开放标签、单臂II期试验,在西班牙和奥地利6个中心开展。
  • 本队列纳入≥18岁、组织学确诊乳腺癌且影像学证实新诊断或局部治疗后进展的脑转移患者,要求至少一个≥10 mm可测量脑病灶且ECOG体能状态0-2。

主要发现

  • 2023年12月12日至2024年7月8日共纳入21例可评估女性患者(luminal型5例、HER2阳性9例、三阴性7例)。
  • 最常见≥3级治疗中出现的不良事件为中性粒细胞减少3例(14%)、腹泻2例(10%)、乏力和呕吐各1例(5%)。
  • 6例(29%)发生严重不良事件,1例(5%)发生与研究治疗相关的2级肺炎,无治疗相关死亡。

关键数值与推荐

  • 主要终点阈值:至少15%的患者达到颅内缓解(依据RANO-BM标准)。

临床怎么用

  • 治疗期间需关注中性粒细胞减少、腹泻等不良事件,并警惕肺炎可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patritumab deruxtecan (HER3-DXd) is a novel antibody-drug conjugate targeting HER3, which is overexpressed in CNS metastases of metastatic breast cancer. We aimed to evaluate the activity and safety of HER3-DXd in patients with metastatic breast cancer and brain metastases that are newly diagnosed or progressing after local therapy. METHODS: TUXEDO-3 trial is a multicohort, multicentre, open-label, single-arm phase 2 trial, done in six sites in Spain and Austria. In this cohort (1 of 3), we enrolled adults (≥18 years) with histologically documented breast cancer and radiologically documented metastatic disease, newly diagnosed brain metastases or brain metastases progressing after local treatment, at least one measurable brain lesion of ≥10 mm, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received HER3-DXd 5·6 mg/kg intravenously once every 3 weeks. The threshold for the primary endpoint was at least 15% of patients having intracranial response according to Response Assessment in Neuro-Oncology Brain Metastases criteria. Activity and safety analyses were done in the full analysis population (ie, all participants who received at least one dose of HER3-DXd). This trial (ClinicalTrials.govNCT05865990 and European Union Clinical Trials Register 2023-503251-10-00) is ongoing and is no longer enrolling patients. FINDINGS: Between Dec 12, 2023, and July 8, 2024, 21 evaluable female patients (five with luminal breast cancer, nine with HER2-positive breast cancer, and seven with triple-negative breast cancer) were recruited. 15 (71%) were White; race was not reported in the remaining six patients. The median number of previous treatment lines for advanced disease was 4 (IQR 2-4). Median treatment duration was 3·0 months (IQR 0·7-7·7), and median follow-up was 4·9 months (IQR 3·6-8·5). The primary endpoint was met with five (24%) of 21 patients having intracranial responses irrespective of the breast cancer subtype (overall response rate 23·8%, 95% CI 8·2-47·1). The most common grade 3 or worse treatment-emergent adverse events were neutropenia in three (14%) patients, diarrhoea in two (10%) patients, and asthenia and vomiting in one (5%) patient each. Serious adverse events occurred in six (29%) patients, with one (5%) patient having grade 2 pneumonitis related to the study treatment. No treatment-related deaths were reported. INTERPRETATION: HER3-DXd showed promising clinical activity in patients with metastatic breast cancer and active brain metastases, and could offer a novel therapeutic option in this setting. FUNDING: Daiichi-Sankyo and Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bartsch R, Marhold M, Garde-Noguera J, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025. PMID: 41167215. doi:10.1016/S1470-2045(25)00470-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。